<DOC>
	<DOC>NCT02375685</DOC>
	<brief_summary>The objective of this study is to evaluate long-term safety of gevokizumab in patient with chronic non-infectious uveitis who previously well tolerated the study drug and may benefit from longterm treatment with gevokizumab.</brief_summary>
	<brief_title>Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>either completed participation to one of the following: CL378989002 openlabel extension, or X052130/CL378989005 doublemasked period or openlabel period, or X052131/CL378989006 doublemasked period or openlabel period, or currently benefiting from gevokizumab compassionate use after participation in gevokizumab uveitis studies Male or female, age ≥18 (or legal age of majority in the country) at selection. For subject with reproductive potential, a willingness to use highly effective contraceptive measures Meeting criteria for discontinuation of any of gevokizumab uveitis previous study. Infectious uveitis and masquerade syndrome History of severe allergic or anaphylactic reaction to study drug administration during previous study or to gevokizumab or any of its excipient. Currently active infectious disease. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Behçet's disease uveitis</keyword>
</DOC>